Suzuki A - Search Results

1

Catatonia as the Initial Manifestation of Dementia with Lewy Bodies.

Saito Y, Noto K, Kobayashi R, Suzuki A, Morioka D, Hayashi H, Otani K. Saito Y, et al. Among authors: suzuki a. Am J Case Rep. 2021 Jul 7;22:e932018. doi: 10.12659/AJCR.932018. Am J Case Rep. 2021. PMID: 34230446 Free PMC article.

2

Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms.

Yasui-Furukori N, Kondo T, Ishida M, Furukori H, Suzuki A, Kaneko S, Inoue M, Otani K. Yasui-Furukori N, et al. Among authors: suzuki a. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan;26(1):53-7. doi: 10.1016/s0278-5846(01)00218-4. Prog Neuropsychopharmacol Biol Psychiatry. 2002. PMID: 11853119 Clinical Trial.

3

Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients.

Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Kaneko S, Otani K. Yasui-Furukori N, et al. Among authors: suzuki a. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):575-8. doi: 10.1016/s0278-5846(01)00310-4. Prog Neuropsychopharmacol Biol Psychiatry. 2002. PMID: 11999910

4

Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome.

Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Sano A, Koshiro K, Otani K, Kaneko S. Mihara K, et al. Among authors: suzuki a. Am J Med Genet B Neuropsychiatr Genet. 2003 Feb;117B(1):57-60. doi: 10.1002/ajmg.b.10025. Am J Med Genet B Neuropsychiatr Genet. 2003. PMID: 12555236

5

Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.

Suzuki A, Yasui-Furukori N, Mihara K, Kondo T, Furukori H, Inoue Y, Kaneko S, Otani K. Suzuki A, et al. Ther Drug Monit. 2003 Apr;25(2):192-6. doi: 10.1097/00007691-200304000-00008. Ther Drug Monit. 2003. PMID: 12657913 Clinical Trial.

6

Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug.

Kato K, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Kanno M, Otani K. Kato K, et al. Among authors: suzuki a. Ther Drug Monit. 2003 Aug;25(4):473-7. doi: 10.1097/00007691-200308000-00010. Ther Drug Monit. 2003. PMID: 12883232 Clinical Trial.

7

Interaction study between fluvoxamine and quazepam.

Kanda H, Yasui-Furukori N, Fukasawa T, Aoshima T, Suzuki A, Otani K. Kanda H, et al. Among authors: suzuki a. J Clin Pharmacol. 2003 Dec;43(12):1392-7. doi: 10.1177/0091270003258667. J Clin Pharmacol. 2003. PMID: 14615476 Clinical Trial.

8

Single oral dose pharmacokinetics of quazepam is influenced by CYP2C19 activity.

Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Tateishi T, Otani K. Fukasawa T, et al. Among authors: suzuki a. Ther Drug Monit. 2004 Oct;26(5):529-33. doi: 10.1097/00007691-200410000-00011. Ther Drug Monit. 2004. PMID: 15385836 Clinical Trial.

9

A three-factor model of the MADRS in major depressive disorder.

Suzuki A, Aoshima T, Fukasawa T, Yoshida K, Higuchi H, Shimizu T, Otani K. Suzuki A, et al. Depress Anxiety. 2005;21(2):95-7. doi: 10.1002/da.20058. Depress Anxiety. 2005. PMID: 15884092

10

Interaction study between enoxacin and fluvoxamine.

Kunii T, Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Tateishi T, Inoue Y, Otani K. Kunii T, et al. Among authors: suzuki a. Ther Drug Monit. 2005 Jun;27(3):349-53. doi: 10.1097/01.ftd.0000159134.94981.3f. Ther Drug Monit. 2005. PMID: 15905806 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,750 results

Search Page

Filters